VEGFA and non-small cell lung carcinoma: A range of anti-VEGF therapeutics have received FDA approval for the treatment of multiple malignancies, including colorectal cancer, cervical cancer, non-small-cell lung cancer (NSCLC), renal cell carcinoma, and several other solid tumors [104].